Derivative exercise or conversion — not an open-market buy.
Traded Mar 10, 2026 · Filed Mar 11, 2026
A board member of Solventum spent $100K of their very own money to buy Solventum shares. Their pile of Solventum shares grew by 41%.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$100,344
Shares × reported transaction price
$100K–$500K
+41.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
12 days after results of Feb 26, 2026, 56 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $67.60 on Mar 10, 2026, 7% above its 52-week low and 22% below its high, after a 14% drop over the previous 30 trading days
52-week range $63.01 (Apr 8, 2025) to $86.14 (Jan 9, 2026), 20% of the way up, from 251 adjusted closes. 30 trading days earlier: $79.01 on Jan 26, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.5% | -0.9% | +2.5% |
| 30 days | +1.9% | +3.0% | -1.1% |
| 90 days | +22.4% | +8.9% | +13.5% |
| 180 days | +36.3% | +15.0% | +21.3% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Derivative exercise or conversion — not an open-market buy.